Investor Presentaiton

Company overview Financial review 2022 priorities Appendix References Simplified organizational model: SG&A savings estimate increased to ~USD 1.5bn fully embedded by 2024 Estimated annual savings Illustrative 2022 Minimal impact, offsetting energy costs and inflation pressure in supply chain 25 Investor Relations | Q2 2022 Results ~USD 1.5bn 2023 2024 One-time restructuring cost now estimated at 1 to 1.2x annual structural savings Integrated Operations unit synergies Simplification of M&S structure (non-customer-facing) Streamlining G&A functions The savings will contribute to achieving mid-long term IM core margins in the low 40's and investing in our pipeline NOVARTIS | Reimagining Medicine

View entire presentation